AJ Vaccines To Develop Vaccine for COVID-19
Danish vaccine manufacturer AJ Vaccines has initiated the development of a new vaccine, effective for protection against coronavirus COVID-19. The vaccine candidate will use technology to raise strong immune responses while being well tolerated and to meet potential global demand in 2021.
COPENHAGEN, Denmark -- (BUSINESS WIRE) --
“This endeavor reiterates our ambition to serve the global community, not only with existing effective high-quality vaccines, but also with the development of innovative new vaccines to answer the current global challenge of coronavirus COVID-19”, says Dr Tabassum Khan, Chairman to AJ Vaccines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200306005124/en/
Committed to prevent serious disease globally
“The impact of the COVID-19 disease globally is developing by the hour and we are committed to a world free of serious diseases across all generations. Our employees are aware of the current challenges and are dedicated to finding solutions to the COVID-19 challenge with state-of-the-art technology”, says Jesper Helmuth Larsen, CEO AJ Vaccines.
High protection, low risk of side effects
“The main principle of vaccination is to proactively induce a protective immune response by mimicking the natural interaction of infectious pathogens with our immune system. Modern antigen technology allows for the production of vaccines combining high protection with a low reactogenicity and favorable safety profile as compared to some of the more traditional vaccines. Our aim is to combine the best possibly designed antigens in such a way to mimic closely the authentic native structures of the virus. Similar technologies were previously successfully applied in US FDA-approved vaccines. In short, the use of such technology is expected to induce the relevant immune responses and therefore protect against disease with a lower risk for side effects”, concludes Jerome Cabannes, COO AJ Vaccines.
Notes for editors
AJ Vaccines Group based in Copenhagen Denmark develop and manufacture vaccines against serious infectious diseases such as tetanus, diphtheria, tuberculosis, pertussis (whooping cough) and polio. In addition, the Group manufactures Tuberculin for screening and diagnosis of high-risk patients for infection with TB, and BCG Culture (Danish strain 1331) for the standard treatment for intermediate and high-risk non-muscle invasive bladder cancer. Our affiliate office in Malaysia focuses on in-licensing and developing, newer more effective vaccines and diagnostics relevant to the region, such as leptospirosis, influenza and cholera.
The company has some 750 employees and expects to expand its skilled workforce in order to fulfill the ambitious growth plans.
See more at: http://www.ajvaccines.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200306005124/en/
世界读书日临近 亲子阅读成全民阅读重头戏
企业元宇宙:员工已准备就绪,组织能否跟上
雅诗兰黛公司宣布Jane Lauder将被任命为企业营销
Sims Limited获选为“2023年亚太区气候领袖”
Intelsat向史密森国家航空航天博物馆捐赠
Elastic任命Barrie Sheers为亚太及日
江西省抚州市委宣传部考察团深入上饶市信州区
诸城市非物质文化遗产“赶大集”活动 在金查
泰雷兹和塔塔通信联手解决企业面临的物联网数
NTT:签订国际热核聚变实验堆(ITER)合作协议
Monde Nissin Complete
Q3医疗器械有限公司与美敦力签署生物可降解胆
Alchemab入选NVIDIA项目,将利用剑桥1号
E和GVK BIO宣布战略研发伙伴关系
第八届“艺庐雅集”在中国美术导报艺术交流基
Engine Biosciences宣布获得超额认购
斯伦贝谢公布2021年第三季度财务业绩
疫情就是命令,防控就是责任,庆云县委党史研
Northleaf Infrastructure C
北京捷越凭实力出圈荣获“2019卓越竞争力金融
迪进国际推出Digi XBee RR模块和快速重新设计服务
北京五棵松:你记忆中的后备箱夜市,来了!
在野泽温泉体验真诚的健康关怀:通过中长期住
平度市人民法院召开“无讼村庄(社区)”创建